2. Cell Cycle/DNA Damage Apoptosis
  3. DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis
  4. SY-589

SY-589 是一种口服有效的 DNA 聚合酶 Polθ 解旋酶结构域抑制剂 (IC50=2.29 nM) 和 DNA 损伤诱导剂。SY-589 可抑制 Polθ 解旋酶结构域的 ATP 酶活性，阻断 Polθ 介导的微同源末端连接 (MMEJ) DNA 修复通路 (IC50=0.85 nM)。SY-589 还通过升高 γ-H2AX 水平诱导 DNA 双链断裂积累。SY-589 可对 BRCA2 缺陷细胞发挥抗增殖作用，用于 HR 缺陷型肿瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

SY-589

SY-589 Chemical Structure

CAS No. : 3077714-09-8

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

SY-589 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC50=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC50=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing γ-H2AX levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors[1].

体外研究
(In Vitro)

SY-589 (第 0、3、6 天处理) 可强效抑制同源重组缺陷型 DLD1 BRCA2-/- 结肠癌细胞的活力，IC50 为 2.71 nM[1]。
SY-589 (0.05-12.8 nM; 10 d) 可在 DLD1 BRCA2-/- 细胞中诱导 DNA 双链断裂呈剂量依赖性累积 (通过 γ-H2AX 水平检测)，并剂量依赖性抑制 DLD1 BRCA2-/- 细胞的克隆形成、诱导细胞周期阻滞和细胞凋亡[1]。
SY-589 (0.39-100 nM; 10 d) 可与 PARP 抑制剂 Olaparib (HY-10162) 产生强烈的协同作用，抑制 DLD1 BRCA2-/- 细胞的活力，显著增强 Olaparib 的抗增殖作用[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SY-589 相关抗体:

Western Blot Analysis[1]

Cell Line: DLD1 BRCA2-/- cells
Concentration: 0.05, 0.2, 0.8, 3.2, 12.8 nM
Incubation Time: 10 days
Result: Induced a dose-dependent increase in γ-H2AX protein levels (a biomarker of DNA double-strand breaks), with the highest fold change observed at 12.8 nM.

Apoptosis Analysis[1]

Cell Line: DLD1 BRCA2-/- cells
Concentration: 0.05, 0.8, 12.8 nM
Incubation Time: 10 days (medium refreshed every 2 days)
Result: Induced dose-dependent changes in cell cycle distribution, increasing the S-phase population from 18.12% (control) to 28.33% at 12.8 nM.
Induced apoptosis in a dose-dependent manner, with the apoptotic rate increasing from 9.13% (control) to 34.2% at 12.8 nM.

Cell Proliferation Assay[1]

Cell Line: DLD1 BRCA2-/- cells
Concentration: 0.05, 0.2, 0.8, 3.2, 12.8 nM
Incubation Time: 12 days (medium refreshed every 2 days)
Result: Suppressed colony formation in a dose-dependent manner, with complete suppression observed at 12.8 nM.

Cell Proliferation Assay[1]

Cell Line: DLD1 BRCA2-/- cells
Concentration: 0.39, 1.56, 6.25, 25, 100 nM (SY-589); serially diluted (Olaparib)
Incubation Time: 10 days (dosed on day 0, day 3, day 6)
Result: Exhibited strong synergistic antiproliferative activity with Olaparib, with a Loewe synergy score of >20.
Enhanced the antiproliferative effect of Olaparib, shifting from no suppression to >50% suppression of cell proliferation when paired with low-dose Olaparib (0.15 nM).
药代动力学
(Parmacokinetics)
Species Dose Route T1/2 Tmax Cmax AUC0-t AUC0-∞ MRT0-t MRT0-∞ Vss CL F
Mice[1] 2 mg/kg i.v. 1.38 h 0.08 h 6661.55 ng/mL 11178.99 ng·h/mL 11454.79 ng·h/mL 1.51 h 1.70 h 0.30 L/kg 2.95 mL/min/kg /
Mice[1] 30 mg/kg p.o. 2.51 h 0.58 h 44547.59 ng/mL 185078.88 ng·h/mL 185274.47 ng·h/mL 4.00 h 4.02 h / / 107.83 %
体内研究
(In Vivo)

SY-589 (0.5-30 mg/kg; p.o.; 每日; 27 d) 可抑制 DLD1BRCA2−/− 异种移植模型中肿瘤生长；而与低剂量 Olaparib (HY-10162) 联合使用时，肿瘤生长抑制率 (TGI) 最高可达 109%，且无显著毒性[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice with Colorectal cancer (female, 6-8 weeks old)[1]
Dosage: 30 mg/kg (monotherapy TGI); 0.5 mg/kg (combination 99% TGI); 2.5 mg/kg (combination 107% TGI); 12.5 mg/kg (combination 109% TGI)
Administration: p.o.; daily; 27 days
Result: Achieved 59% tumor growth inhibition (TGI) as monotherapy.
Achieved 99% TGI in combination with 25 mg/kg Olaparib.
Achieved 107% TGI with marked tumor regression in combination with 25 mg/kg Olaparib.
Achieved 109% TGI with marked tumor regression in combination with 25 mg/kg Olaparib.
Caused no significant body weight changes in any treatment group during the study.
分子量

552.97

Formula

C24H18ClFN8O3S
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

SY-589 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SY-5893077714-09-8SY589SY 589DNA Alkylator/CrosslinkerDNA/RNA SynthesisApoptosisATPase activityhuman Polθ helicase domainmicro-homology-mediated end joiningHR-deficient tumorsDLD1 BRCA2-/- colon cancer cellshomologous recombination-deficient cellsDNA polymerase theta helicase domainBRCA2-deficient cellsγ-H2AXDNA double-strand breaksInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
SY-589
目录号：
HY-181557
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z